{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:40:17Z","timestamp":1792676417268,"version":"4.5.0"},"reference-count":305,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00848-3","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:05:11Z","timestamp":1792670711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation"],"prefix":"10.1186","volume":"15","author":[{"given":"Peng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenLin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunFeng","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7042-718X","authenticated-orcid":false,"given":"Xingchen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"848_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-026-02609-6","author":"K Okuyama","year":"2026","unstructured":"Okuyama K, Naruse T, Matsushita Y, Fujimoto J, Yanamoto S, Lei YL, et al. Precision immunotherapy for head and neck cancer: therapeutic combinations, biomarker strategies, and translational challenges. Mol Cancer. 2026. https:\/\/doi.org\/10.1186\/s12943-026-02609-6.","journal-title":"Mol Cancer"},{"key":"848_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2025.12.009","author":"ISC van Rossum","year":"2026","unstructured":"van Rossum ISC, van Spriel AB, van Mierlo G. Decoding the immune-tumor synapse for data-driven design of next-generation immunotherapies. Trends Immunol. 2026. https:\/\/doi.org\/10.1016\/j.it.2025.12.009.","journal-title":"Trends Immunol"},{"key":"848_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202522864","author":"E Frosteg\u00e5rd","year":"2026","unstructured":"Frosteg\u00e5rd E, Bobrova T, Leineb\u00f8 A, Leray T, Ghosh S, Garc\u00eda-Hevia L, et al. Nanomedicine meets immunotherapy: advancing adoptive cell therapy with nanoparticles in the treatment of cancer with sustainability perspectives. Adv Sci. 2026. https:\/\/doi.org\/10.1002\/advs.202522864.","journal-title":"Adv Sci"},{"key":"848_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.114752","volume":"393","author":"A Baez","year":"2026","unstructured":"Baez A, Hazel K, Guertin Z, Fong E, Mc Manus M, Kaloyannis A, et al. Thermal sonogenetics for adoptive cell transfer therapy. J Control Release. 2026;393:114752.","journal-title":"J Control Release"},{"key":"848_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbag007","volume":"9","author":"X Liu","year":"2026","unstructured":"Liu X, Gao H, Yu J. Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases. Precis Clin Med. 2026;9:pbag007.","journal-title":"Precis Clin Med"},{"key":"848_CR6","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1200\/JCO-25-02087","volume":"44","author":"RG Faramand","year":"2026","unstructured":"Faramand RG, Xie Z, Jain MD. Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies. J Clin Oncol. 2026;44:698\u2013708.","journal-title":"J Clin Oncol"},{"key":"848_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202522140","volume":"38","author":"C Zhu","year":"2026","unstructured":"Zhu C, Sun Z, Wu Q, Wang F, Zhang L, Wang W, et al. Engineered bacterial biomaterials for augmenting adoptive immune cell therapy against solid tumors. Adv Mater. 2026;38:e22140.","journal-title":"Adv Mater"},{"key":"848_CR8","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1084\/jem.155.6.1823","volume":"155","author":"EA Grimm","year":"1982","unstructured":"Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823\u201341.","journal-title":"J Exp Med"},{"key":"848_CR9","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/1097-0142(19850315)55:6<1327::AID-CNCR2820550628>3.0.CO;2-O","volume":"55","author":"AA Rayner","year":"1985","unstructured":"Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer. 1985;55:1327\u201333.","journal-title":"Cancer"},{"key":"848_CR10","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485\u201392.","journal-title":"N Engl J Med"},{"key":"848_CR11","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318\u201321.","journal-title":"Science"},{"key":"848_CR12","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319:1676\u201380.","journal-title":"N Engl J Med"},{"key":"848_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0008-8749(86)90015-8","volume":"100","author":"T Nishimura","year":"1986","unstructured":"Nishimura T, Yagi H, Uchiyama Y, Hashimoto Y. Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes. Cell Immunol. 1986;100:149\u201357.","journal-title":"Cell Immunol"},{"key":"848_CR14","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550\u20137.","journal-title":"Clin Cancer Res"},{"key":"848_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJM198704093161501","volume":"316","author":"SA Rosenberg","year":"1987","unstructured":"Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889\u201397.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"848_CR16","first-page":"S21","volume":"25","author":"S Negrier","year":"1989","unstructured":"Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C, et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol. 1989;25(Suppl 3):S21\u201328.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"848_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030663","author":"YJ Chen","year":"2023","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y. CAR-T: what is next? Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15030663.","journal-title":"Cancers (Basel)"},{"key":"848_CR18","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"848_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725\u201333.","journal-title":"N Engl J Med"},{"key":"848_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2017.156","volume":"15","author":"V Prasad","year":"2018","unstructured":"Prasad V. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol. 2018;15:11\u20132.","journal-title":"Nat Rev Clin Oncol"},{"key":"848_CR21","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-21-0115","volume":"20","author":"Z Duan","year":"2021","unstructured":"Duan Z, Ho M. T-cell receptor mimic antibodies for cancer immunotherapy. Mol Cancer Ther. 2021;20:1533\u201341.","journal-title":"Mol Cancer Ther"},{"key":"848_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40265-022-01704-4","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon S. Tebentafusp: first approval. Drugs. 2022;82:703\u201310.","journal-title":"Drugs"},{"key":"848_CR23","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021;385:1196\u2013206.","journal-title":"N Engl J Med"},{"key":"848_CR24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947\u201353.","journal-title":"Nat Biotechnol"},{"key":"848_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.","journal-title":"EBioMedicine"},{"key":"848_CR26","volume":"9","author":"X Huang","year":"2022","unstructured":"Huang X, Zhang G, Tang TY, Gao X, Liang TB. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil Med Res. 2022;9:53.","journal-title":"Mil Med Res"},{"key":"848_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15:28.","journal-title":"J Hematol Oncol"},{"key":"848_CR28","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1158\/1078-0432.CCR-13-2671","volume":"20","author":"OE Rahma","year":"2014","unstructured":"Rahma OE, Gammoh E, Simon RM, Khleif SN. Is the \u201c3\u2009+\u20093\u201d dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design. Clin Cancer Res. 2014;20:4758\u201367.","journal-title":"Clin Cancer Res"},{"key":"848_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40425-015-0093-x","volume":"3","author":"AC Tan","year":"2015","unstructured":"Tan AC, Goubier A, Kohrt HE. A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. J Immunother Cancer. 2015;3:48.","journal-title":"J Immunother Cancer"},{"key":"848_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00281-022-00966-0","volume":"45","author":"MH Andersen","year":"2023","unstructured":"Andersen MH. Tumor microenvironment antigens. Semin Immunopathol. 2023;45:253\u201364.","journal-title":"Semin Immunopathol"},{"key":"848_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023;8:450.","journal-title":"Signal Transduct Target Ther"},{"key":"848_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102973","volume":"138","author":"N Dusetti","year":"2025","unstructured":"Dusetti N, Bachet JB, Chanez B, Neuzillet C, de Mestier L, Williet N, et al. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Cancer Treat Rev. 2025;138:102973.","journal-title":"Cancer Treat Rev"},{"key":"848_CR33","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1158\/2159-8290.CD-25-0300","volume":"15","author":"DJ Martini","year":"2025","unstructured":"Martini DJ, Wu CJ. The future of personalized cancer vaccines. Cancer Discov. 2025;15:1315\u201324.","journal-title":"Cancer Discov"},{"key":"848_CR34","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632\u201344.","journal-title":"Lancet"},{"key":"848_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024;30:531\u201342.","journal-title":"Nat Med"},{"key":"848_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.canlet.2003.07.003","volume":"201","author":"SA Nicklin","year":"2003","unstructured":"Nicklin SA, Dishart KL, Buening H, Reynolds PN, Hallek M, Nemerow GR, et al. Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. Cancer Lett. 2003;201:165\u201373.","journal-title":"Cancer Lett"},{"key":"848_CR37","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"848_CR38","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone MC, O\u2019Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32:1529\u201341.","journal-title":"Leukemia"},{"key":"848_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7:10541.","journal-title":"Sci Rep"},{"key":"848_CR40","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 2018;23:2130\u201341.","journal-title":"Cell Rep"},{"key":"848_CR41","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","volume":"24","author":"V Hoyos","year":"2010","unstructured":"Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety. Leukemia. 2010;24:1160\u201370.","journal-title":"Leukemia"},{"key":"848_CR42","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1182\/blood-2012-02-412973","volume":"120","author":"Q Zhou","year":"2012","unstructured":"Zhou Q, Schneider IC, Edes I, Honegger A, Bach P, Sch\u00f6nfeld K, Schambach A, Wels WS, Kneissl S, Uckert W, Buchholz CJ. T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood. 2012;120:4334\u201342.","journal-title":"Blood"},{"key":"848_CR43","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/mto.2016.10","volume":"3","author":"TC Albershardt","year":"2016","unstructured":"Albershardt TC, Campbell DJ, Parsons AJ, Slough MM, Ter Meulen J, Berglund P. LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response. Mol Ther Oncolytics. 2016;3:16010.","journal-title":"Mol Ther Oncolytics"},{"key":"848_CR44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.20892\/j.issn.2095-3941.2025.0149","volume":"22","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zhang M, Li M, Zong L, Ye Q, Lei W, et al. A novel BaEVRless-LV packaging system for the production of lentiviral vectors for clinical-grade CAR-NK cell manufacturing. Cancer Biol Med. 2025;22:137\u201343.","journal-title":"Cancer Biol Med"},{"key":"848_CR45","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/mt.2010.278","volume":"19","author":"K Cornetta","year":"2011","unstructured":"Cornetta K, Yao J, Jasti A, Koop S, Douglas M, Hsu D, et al. Replication-competent lentivirus analysis of clinical grade vector products. Mol Ther. 2011;19:557\u201366.","journal-title":"Mol Ther"},{"key":"848_CR46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307800120","volume":"121","author":"S Chatterjee","year":"2024","unstructured":"Chatterjee S, Kon E, Sharma P, Peer D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc Natl Acad Sci U S A. 2024;121:e2307800120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"848_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, Gong N, Mukalel AJ, Thatte AS, El-Mayta R, Patel SK, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small. 2024;20:e2304378.","journal-title":"Small"},{"key":"848_CR48","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1016\/j.ymthe.2025.08.028","volume":"33","author":"TR Lunavat","year":"2025","unstructured":"Lunavat TR, Nieland L, van de Looij SM, de Reus A, Couturier CP, El Farran CA, Miller TE, Lill JK, Sch\u00fcbel M, Xiao T, et al. Intratumoral delivery of 4-1BBL boosts IL-12-triggered anti-glioma immunity. Mol Ther. 2025;33:5530\u201355.","journal-title":"Mol Ther"},{"key":"848_CR49","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816\u201321.","journal-title":"Science"},{"key":"848_CR50","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"CA Lino","year":"2018","unstructured":"Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018;25:1234\u201357.","journal-title":"Drug Deliv"},{"key":"848_CR51","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMx160005","volume":"374","author":"Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia","year":"2016","unstructured":"Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2016;374:998.","journal-title":"N Engl J Med"},{"key":"848_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-026-00822-z","author":"Y Mai","year":"2026","unstructured":"Mai Y, Wang Z, Wang J, Song M, Xiang T, He Y, et al. Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies. Exp Hematol Oncol. 2026. https:\/\/doi.org\/10.1186\/s40164-026-00822-z.","journal-title":"Exp Hematol Oncol"},{"key":"848_CR53","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2026.0154","author":"J Zhang","year":"2026","unstructured":"Zhang J, Li S, Ma X, You X, Li H, Chen C, Fan D, Nie Y, Wu K, Huang W, Xia L. Revisiting the immunosuppressive microenvironment in hepatocellular carcinoma: a functional taxonomy of immune cells and therapeutic targeting. Cancer Biol Med. 2026. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2026.0154.","journal-title":"Cancer Biol Med"},{"key":"848_CR54","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189\u201398.","journal-title":"Nat Med"},{"key":"848_CR55","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30:2224\u201334.","journal-title":"Nat Med"},{"key":"848_CR56","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405:2049\u201360.","journal-title":"Lancet"},{"key":"848_CR57","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/hep.30326","volume":"70","author":"Y Fu","year":"2019","unstructured":"Fu Y, Urban DJ, Nani RR, Zhang YF, Li N, Fu H, Shah H, Gorka AP, Guha R, Chen L, et al. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma. Hepatology. 2019;70:563\u201376.","journal-title":"Hepatology"},{"key":"848_CR58","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","volume":"26","author":"D Shi","year":"2020","unstructured":"Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, Lu Q, Gao H, Jiang H, Wang H, et al. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clin Cancer Res. 2020;26:3979\u201389.","journal-title":"Clin Cancer Res"},{"key":"848_CR59","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637:940\u20136.","journal-title":"Nature"},{"key":"848_CR60","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41586-026-10786-z","volume":"657","author":"Q Zhang","year":"2026","unstructured":"Zhang Q, Fu Q, Shen Y, Cao W, Jin G, Zhang Y, Wu J, Chen C, Wang H, Xu X, et al. GPC3-specific dnTGF\u03b2RII-armoured CAR T cells for hepatocellular carcinoma. Nature. 2026;657:495\u2013504.","journal-title":"Nature"},{"key":"848_CR61","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388:1284\u201395.","journal-title":"N Engl J Med"},{"key":"848_CR62","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO-25-01090","volume":"44","author":"C Qi","year":"2026","unstructured":"Qi C, Liu C, Gong J, Wang X, Wang Z, Xu T, Liu D, Zhang P, Li J, Zhang M, et al. Guanylyl Cyclase 2\u00a0C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2026;44:2006\u201316.","journal-title":"J Clin Oncol"},{"key":"848_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-68112-6","volume":"17","author":"X Li","year":"2026","unstructured":"Li X, Shang X, Liu J, Zhang Y, Jia X, Li H, et al. Intrathecal CRISPR-edited allogeneic IL-13R\u03b12 CAR T cells for recurrent high-grade glioma: preclinical characterization and phase I trial. Nat Commun. 2026;17:1362.","journal-title":"Nat Commun"},{"key":"848_CR64","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1200\/JCO.23.02229","volume":"42","author":"N Pinto","year":"2024","unstructured":"Pinto N, Albert CM, Taylor MR, Ullom HB, Wilson AL, Huang W, et al. STRIvE-02: a first-in-human phase I study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with relapsed\/refractory solid tumors. J Clin Oncol. 2024;42:4163\u201372.","journal-title":"J Clin Oncol"},{"key":"848_CR65","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","volume":"14","author":"SK Pal","year":"2024","unstructured":"Pal SK, Tran B, Haanen J, Hurwitz ME, Sacher A, Tannir NM, et al. CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma. Cancer Discov. 2024;14:1176\u201389.","journal-title":"Cancer Discov"},{"key":"848_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10:210.","journal-title":"Signal Transduct Target Ther"},{"key":"848_CR67","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843\u201351.","journal-title":"Mol Ther"},{"key":"848_CR68","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-024-00983-2","volume":"14","author":"T Zhou","year":"2024","unstructured":"Zhou T, Curry CV, Khanlari M, Shi M, Cui W, Peker D, Chen W, Wang E, Gao J, Shen Q, et al. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood Cancer J. 2024;14:19.","journal-title":"Blood Cancer J"},{"key":"848_CR69","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1186\/s12964-024-01894-2","volume":"22","author":"Y Chen","year":"2024","unstructured":"Chen Y, Xin Q, Zhu M, Qiu J, Qiu J, Li R, Tu J. Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape. Cell Commun Signal. 2024;22:521.","journal-title":"Cell Commun Signal"},{"key":"848_CR70","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21:524\u20139.","journal-title":"Nat Med"},{"key":"848_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019;10:4016.","journal-title":"Nat Commun"},{"key":"848_CR72","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"key":"848_CR73","first-page":"2460","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141:2460\u20139.","journal-title":"Blood"},{"key":"848_CR74","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","volume":"46","author":"AD Hughes","year":"2024","unstructured":"Hughes AD, Teachey DT, Diorio C. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Semin Immunopathol. 2024;46:5.","journal-title":"Semin Immunopathol"},{"key":"848_CR75","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1182\/bloodadvances.2024015314","volume":"9","author":"J Gauthier","year":"2025","unstructured":"Gauthier J, Liang EC, Huang JJ, Kimble EL, Hirayama AV, Fiorenza S, Voutsinas JM, Wu QV, Jaeger-Ruckstuhl CA, Pender BS, et al. Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-na\u00efve adult patients with B-ALL. Blood Adv. 2025;9:1861\u201372.","journal-title":"Blood Adv"},{"key":"848_CR76","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","volume":"9","author":"A Looka","year":"2025","unstructured":"Looka A, Qualls DA, Matthews D, Redd RA, Sakellis C, Duffy C, et al. A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma. Blood Adv. 2025;9:455\u201362.","journal-title":"Blood Adv"},{"key":"848_CR77","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40487-023-00228-5","volume":"11","author":"S Jagannath","year":"2023","unstructured":"Jagannath S, Joseph N, Crivera C, Kharat A, Jackson CC, Valluri S, et al. Component costs of CAR-T therapy in addition to treatment acquisition costs in patients with multiple myeloma. Oncol Ther. 2023;11:263\u201375.","journal-title":"Oncol Ther"},{"key":"848_CR78","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025;31:1171\u201382.","journal-title":"Nat Med"},{"key":"848_CR79","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, K\u00fcnkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med. 2021;27:1544\u201352.","journal-title":"Nat Med"},{"key":"848_CR80","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, et al. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov. 2021;11:2748\u201363.","journal-title":"Cancer Discov"},{"key":"848_CR81","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41416-023-02319-6","volume":"129","author":"X Dong","year":"2023","unstructured":"Dong X, Fan J, Xie W, Wu X, Wei J, He Z, Wang W, Wang X, Shen P, Bei Y. Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer. Br J Cancer. 2023;129:551\u201362.","journal-title":"Br J Cancer"},{"key":"848_CR82","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","volume":"13","author":"J Li","year":"2024","unstructured":"Li J, Chen P, Ma W. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp Hematol Oncol. 2024;13:76.","journal-title":"Exp Hematol Oncol"},{"key":"848_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-026-02650-3","author":"T Shibata","year":"2026","unstructured":"Shibata T, Bhat S, Cao D, Saito S, Khan N, Bernstein EA, et al. Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth. Signal Transduct Target Ther. 2026. https:\/\/doi.org\/10.1038\/s41392-026-02650-3.","journal-title":"Signal Transduct Target Ther"},{"key":"848_CR84","doi-asserted-by":"publisher","first-page":"115713","DOI":"10.1016\/j.addr.2025.115713","volume":"227","author":"D Bas\u00edlio-Queir\u00f3s","year":"2025","unstructured":"Bas\u00edlio-Queir\u00f3s D, Rivi\u00e8re I, van der Stegen SJC, Lachmann N. iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches. Adv Drug Deliv Rev. 2025;227:115713.","journal-title":"Adv Drug Deliv Rev"},{"key":"848_CR85","doi-asserted-by":"publisher","first-page":"19163","DOI":"10.1021\/acsnano.5c21015","volume":"20","author":"YQ Sun","year":"2026","unstructured":"Sun YQ, Shang HM, Wang MD, Huang MW, Qing YX, Cai YY, et al. Engineering interferon-\u03b3-enhanced chimeric antigen receptor macrophages via lipid-assisted polymeric nanoparticles for cancer immunotherapy. ACS Nano. 2026;20:19163\u201379.","journal-title":"ACS Nano"},{"key":"848_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-026-02962-5","author":"S Wang","year":"2026","unstructured":"Wang S, Zhou L, Chen X, Xu Z, Chen Y, Lin N, et al. In vivo CAR-M therapy: advancing precision delivery and programmable immune remodeling. Cell Commun Signal. 2026. https:\/\/doi.org\/10.1186\/s12964-026-02962-5.","journal-title":"Cell Commun Signal"},{"key":"848_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-026-00447-y","author":"YM Yang","year":"2026","unstructured":"Yang YM, Bao B, Cao YH, Yao J, Ding YF, Hu YY, et al. In vivo CAR-cell therapy: current challenges and emerging therapeutic advances. Mol Biomed. 2026. https:\/\/doi.org\/10.1186\/s43556-026-00447-y.","journal-title":"Mol Biomed"},{"key":"848_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22:20.","journal-title":"Mol Cancer"},{"key":"848_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01382-5","volume":"15","author":"N Lamers-Kok","year":"2022","unstructured":"Lamers-Kok N, Panella D, Georgoudaki AM, Liu H, \u00d6zkazanc D, Ku\u010derov\u00e1 L, et al. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J Hematol Oncol. 2022;15:164.","journal-title":"J Hematol Oncol"},{"key":"848_CR90","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2147\/ITT.S490498","volume":"13","author":"S Chen","year":"2024","unstructured":"Chen S, Yang L, Xia B, Zhu H, Piao Z, Jounaidi Y. A self-activating IL-15 chimeric cytokine receptor to empower cancer immunotherapy. Immunotargets Ther. 2024;13:513\u201324.","journal-title":"Immunotargets Ther"},{"key":"848_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun. 2024;15:8439.","journal-title":"Nat Commun"},{"key":"848_CR92","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","volume":"31","author":"JL Thangaraj","year":"2024","unstructured":"Thangaraj JL, Coffey M, Lopez E, Kaufman DS. Disruption of TGF-\u03b2 signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells. Cell Stem Cell. 2024;31:1327\u2013e13431325.","journal-title":"Cell Stem Cell"},{"key":"848_CR93","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943-023-01722-0","volume":"22","author":"Z Gao","year":"2023","unstructured":"Gao Z, Bai Y, Lin A, Jiang A, Zhou C, Cheng Q, Liu Z, Chen X, Zhang J, Luo P. Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. Mol Cancer. 2023;22:31.","journal-title":"Mol Cancer"},{"key":"848_CR94","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1182\/bloodadvances.2019032409","volume":"3","author":"GJJ Kierkels","year":"2019","unstructured":"Kierkels GJJ, Scheper W, Meringa AD, Johanna I, Beringer DX, Janssen A, et al. Identification of a tumor-specific allo-HLA-restricted \u03b3\u03b4TCR. Blood Adv. 2019;3:2870\u201382.","journal-title":"Blood Adv"},{"key":"848_CR95","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/ni.1841","volume":"11","author":"DI Godfrey","year":"2010","unstructured":"Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol. 2010;11:197\u2013206.","journal-title":"Nat Immunol"},{"key":"848_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6:362.","journal-title":"Signal Transduct Target Ther"},{"key":"848_CR97","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","volume":"23","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Tahmasebi S, Esmaeilzadeh A. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell Int. 2023;23:86.","journal-title":"Cancer Cell Int"},{"key":"848_CR98","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","volume":"29","author":"A Heczey","year":"2023","unstructured":"Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023;29:1379\u201388.","journal-title":"Nat Med"},{"key":"848_CR99","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1016\/j.ymthe.2025.09.026","volume":"33","author":"YR Li","year":"2025","unstructured":"Li YR, Zhu Y, Li Z, Shen X, Halladay T, Tse C, Tian Y, Huang J, Zhao AS, Ma NY, et al. Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety. Mol Ther. 2025;33:6041\u201362.","journal-title":"Mol Ther"},{"key":"848_CR100","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-025-01736-9","volume":"18","author":"YR Li","year":"2025","unstructured":"Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, et al. Targeting triple-negative breast cancer using cord-blood CD34\u207a HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025;18:86.","journal-title":"J Hematol Oncol"},{"key":"848_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102321","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Hu J, Li Z, Zhu E, Chen Y, Halladay T, et al. Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell Rep Med. 2025;6:102321.","journal-title":"Cell Rep Med"},{"key":"848_CR102","first-page":"1310","volume":"9","author":"YR Li","year":"2026","unstructured":"Li YR, Zhu Y, Li Z, Shen X, Li S, Chen Y, Lyu Z, Huang J, Ma NY, Zhang C, et al. Rejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural Mesothelioma. Res (Wash D C). 2026;9:1310.","journal-title":"Res (Wash D C)"},{"key":"848_CR103","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2517786122","volume":"122","author":"YR Li","year":"2025","unstructured":"Li YR, Shen X, Zhu E, Li Z, Huang J, Le T, et al. Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected CAR-NKT cells. Proc Natl Acad Sci U S A. 2025;122:e2517786122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"848_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.08.002","author":"B Navarro Rodrigo","year":"2025","unstructured":"Navarro Rodrigo B, Ortiz Miranda Y, Corria-Osorio J, Coukos G, Harari A. Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps. Trends Cancer. 2025. https:\/\/doi.org\/10.1016\/j.trecan.2025.08.002.","journal-title":"Trends Cancer"},{"issue":"8","key":"848_CR105","first-page":"718","volume":"26","author":"IVC Mustahidul Islam","year":"2025","unstructured":"Mustahidul Islam IVC, Bishnoi M, Priya M, Das Kurmi S, Koshey B, Patel S. Lifileucel Therapy for Metastatic Melanoma: Advancements in Tumor-infiltrating Lymphocyte-based Immunotherapy. Anticancer Agents Med Chem. 2025;26(8):718\u201330.","journal-title":"Anticancer Agents Med Chem"},{"key":"848_CR106","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000566","volume":"4","author":"R Chen","year":"2025","unstructured":"Chen R, Johnson J, Rezazadeh A, Dudek AZ. Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges. BMJ Oncol. 2025;4:e000566.","journal-title":"BMJ Oncol"},{"key":"848_CR107","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011066","author":"RAM Rossetti","year":"2025","unstructured":"Rossetti RAM, Tordesillas L, Beatty MS, Cianne J, Martinez Planes E, Du D, et al. CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-011066.","journal-title":"J Immunother Cancer"},{"key":"848_CR108","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1158\/1078-0432.CCR-22-2428","volume":"29","author":"TJ Monberg","year":"2023","unstructured":"Monberg TJ, Borch TH, Svane IM, Donia M. TIL therapy: facts and hopes. Clin Cancer Res. 2023;29:3275\u201383.","journal-title":"Clin Cancer Res"},{"key":"848_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174160","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F, et al. Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14174160.","journal-title":"Cancers (Basel)"},{"key":"848_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100702","volume":"6","author":"P Wiertsema","year":"2025","unstructured":"Wiertsema P, Tan YH, Haanen J, Seijkens TTP, Jedema I. Advances in TIL therapy: expanding the horizons beyond melanoma. Med. 2025;6:100702.","journal-title":"Med"},{"key":"848_CR111","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233\u20139.","journal-title":"J Clin Oncol"},{"key":"848_CR112","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.annonc.2024.07.723","volume":"35","author":"S Mart\u00edn-Lluesma","year":"2024","unstructured":"Mart\u00edn-Lluesma S, Svane IM, Dafni U, Vervita K, Karlis D, Dimopoulou G, Tsourti Z, Rohaan MW, Haanen J, Coukos G. Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis. Ann Oncol. 2024;35:860\u201372.","journal-title":"Ann Oncol"},{"key":"848_CR113","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","author":"J Chesney","year":"2022","unstructured":"Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005755.","journal-title":"J Immunother Cancer"},{"key":"848_CR114","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","volume":"14","author":"AJ Schoenfeld","year":"2024","unstructured":"Schoenfeld AJ, Lee SM, Doger de Sp\u00e9ville B, Gettinger SN, H\u00e4fliger S, Sukari A, et al. Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors. Cancer Discov. 2024;14:1389\u2013402.","journal-title":"Cancer Discov"},{"key":"848_CR115","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27:1410\u20138.","journal-title":"Nat Med"},{"key":"848_CR116","first-page":"492","volume":"9","author":"D O\u2019Malley","year":"2021","unstructured":"O\u2019Malley D, Lee S, Psyrri A, Sukari A, Thomas S, Wenham R, Gogas H, Jazaeri A, Monk B, Rose P, et al. 492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-na\u00efve patients with advanced cancers. J Immunother Cancer. 2021;9:492.","journal-title":"J Immunother Cancer"},{"key":"848_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02006-4","volume":"19","author":"S Wang","year":"2021","unstructured":"Wang S, Sun J, Chen K, Ma P, Lei Q, Xing S, et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med. 2021;19:140.","journal-title":"BMC Med"},{"key":"848_CR118","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/med.21727","volume":"41","author":"MA Hossain","year":"2021","unstructured":"Hossain MA, Liu G, Dai B, Si Y, Yang Q, Wazir J, Birnbaumer L, Yang Y. Reinvigorating exhausted CD8(+) cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Med Res Rev. 2021;41:156\u2013201.","journal-title":"Med Res Rev"},{"key":"848_CR119","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.cell.2016.08.052","volume":"166","author":"M Singer","year":"2016","unstructured":"Singer M, Wang C, Cong L, Marjanovic ND, Kowalczyk MS, Zhang H, et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell. 2016;166:1500-1511.e1509.","journal-title":"Cell"},{"key":"848_CR120","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s11899-019-00523-x","volume":"14","author":"GP Linette","year":"2019","unstructured":"Linette GP, Carreno BM. Tumor-infiltrating lymphocytes in the checkpoint inhibitor era. Curr Hematol Malig Rep. 2019;14:286\u201391.","journal-title":"Curr Hematol Malig Rep"},{"key":"848_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1228331","volume":"14","author":"Y Ma","year":"2023","unstructured":"Ma Y, Xu X, Wang H, Liu Y, Piao H. Non-coding RNA in tumor-infiltrating regulatory T cells formation and associated immunotherapy. Front Immunol. 2023;14:1228331.","journal-title":"Front Immunol"},{"key":"848_CR122","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9:eadf3700.","journal-title":"Sci Adv"},{"key":"848_CR123","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41421-018-0066-6","volume":"4","author":"Y Xu","year":"2018","unstructured":"Xu Y, Yang Z, Horan LH, Zhang P, Liu L, Zimdahl B, Green S, Lu J, Morales JF, Barrett DM, et al. A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma\/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. Cell Discov. 2018;4:62.","journal-title":"Cell Discov"},{"key":"848_CR124","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nbt.4090","volume":"36","author":"K Garber","year":"2018","unstructured":"Garber K. Driving T-cell immunotherapy to solid tumors. Nat Biotechnol. 2018;36:215\u20139.","journal-title":"Nat Biotechnol"},{"key":"848_CR125","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jconrel.2024.02.033","volume":"368","author":"T Zhang","year":"2024","unstructured":"Zhang T, Tai Z, Miao F, Zhang X, Li J, Zhu Q, et al. Adoptive cell therapy for solid tumors beyond CAR-T: current challenges and emerging therapeutic advances. J Control Release. 2024;368:372\u201396.","journal-title":"J Control Release"},{"key":"848_CR126","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41422-022-00627-9","volume":"32","author":"J He","year":"2022","unstructured":"He J, Xiong X, Yang H, Li D, Liu X, Li S, et al. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Res. 2022;32:530\u201342.","journal-title":"Cell Res"},{"key":"848_CR127","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3724\/abbs.2024091","volume":"56","author":"X Zhao","year":"2024","unstructured":"Zhao X, Shao S, Hu L. The recent advancement of TCR-T cell therapies for cancer treatment. Acta Biochim Biophys Sin (Shanghai). 2024;56:663\u201374.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"848_CR128","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1002\/ijc.34453","volume":"152","author":"M Ishihara","year":"2023","unstructured":"Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, et al. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. Int J Cancer. 2023;152:2554\u201366.","journal-title":"Int J Cancer"},{"key":"848_CR129","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024105","author":"EF Krakow","year":"2024","unstructured":"Krakow EF, Brault M, Summers C, Cunningham TM, Biernacki MA, Black RG, et al. HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation. Blood. 2024. https:\/\/doi.org\/10.1182\/blood.2024024105.","journal-title":"Blood"},{"key":"848_CR130","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008668","author":"M Wermke","year":"2024","unstructured":"Wermke M, Holderried TAW, Luke JJ, Morris VK, Alsdorf WH, Wetzko K, et al. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-008668.","journal-title":"J Immunother Cancer"},{"key":"848_CR131","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/gutjnl-2025-335456","volume":"75","author":"X Wu","year":"2025","unstructured":"Wu X, Quan D, Li W, Wisskirchen K, Wu W, Zhou Y, et al. Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial. Gut. 2025;75:147\u201360.","journal-title":"Gut"},{"key":"848_CR132","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403:1460\u201371.","journal-title":"Lancet"},{"key":"848_CR133","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003581","author":"GR Blumenschein","year":"2022","unstructured":"Blumenschein GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman MJ, et al. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003581.","journal-title":"J Immunother Cancer"},{"key":"848_CR134","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-23-1456","volume":"29","author":"A Kawai","year":"2023","unstructured":"Kawai A, Ishihara M, Nakamura T, Kitano S, Iwata S, Takada K, Emori M, Kato K, Endo M, Matsumoto Y, et al. Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I\/II Clinical Trial. Clin Cancer Res. 2023;29:5069\u201378.","journal-title":"Clin Cancer Res"},{"key":"848_CR135","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D'Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma. Cancer Discov. 2018;8:944\u201357.","journal-title":"Cancer Discov"},{"issue":"9","key":"848_CR136","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S1470-2045(19)30541-8","volume":"20","author":"TK Burki","year":"2019","unstructured":"Burki TK. TCR gene therapy for HPV-associated epithelial cancers. Lancet Oncol. 2019;20:e474.","journal-title":"Lancet Oncol"},{"key":"848_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46558-4","volume":"15","author":"J Long","year":"2024","unstructured":"Long J, Chen X, He M, Ou S, Zhao Y, Yan Q, et al. HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice. Nat Commun. 2024;15:2271.","journal-title":"Nat Commun"},{"key":"848_CR138","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s12072-023-10524-x","volume":"17","author":"F Yang","year":"2023","unstructured":"Yang F, Zheng X, Koh S, Lu J, Cheng J, Li P, Du C, Chen Y, Chen X, Yang L, et al. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial. Hepatol Int. 2023;17:850\u20139.","journal-title":"Hepatol Int"},{"key":"848_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42010-1","volume":"14","author":"D Lu","year":"2023","unstructured":"Lu D, Chen Y, Jiang M, Wang J, Li Y, Ma K, et al. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. Nat Commun. 2023;14:6389.","journal-title":"Nat Commun"},{"key":"848_CR140","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","volume":"10","author":"SP Kim","year":"2022","unstructured":"Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, Gartner JJ, Sindiri S, Malekzadeh P, Deniger DC, et al. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. Cancer Immunol Res. 2022;10:932\u201346.","journal-title":"Cancer Immunol Res"},{"key":"848_CR141","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41591-022-01786-3","volume":"28","author":"SS Chandran","year":"2022","unstructured":"Chandran SS, Ma J, Klatt MG, D\u00fcndar F, Bandlamudi C, Razavi P, et al. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 2022;28:946\u201357.","journal-title":"Nat Med"},{"key":"848_CR142","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s11658-024-00561-1","volume":"29","author":"X Chen","year":"2024","unstructured":"Chen X, Zhong S, Zhan Y, Zhang X. CRISPR-Cas9 applications in T cells and adoptive T cell therapies. Cell Mol Biol Lett. 2024;29:52.","journal-title":"Cell Mol Biol Lett"},{"key":"848_CR143","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012505","author":"F Hu","year":"2025","unstructured":"Hu F, Li H, Lv W, Li M, Gale RP, Huang X, et al. Mapping the cancer vaccine landscape. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-012505.","journal-title":"J Immunother Cancer"},{"key":"848_CR144","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567:479\u201385.","journal-title":"Nature"},{"key":"848_CR145","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11684-026-1210-6","volume":"20","author":"N Qiao","year":"2026","unstructured":"Qiao N, Chen J-X, Liu Y, Chen Z, Chen S-J. mRNA vaccines in cancer immunotherapy: current progress and perspectives in solid tumors and hematologic malignancies. MedScience. 2026;20:23\u201358.","journal-title":"MedScience"},{"key":"848_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2026.126765","author":"CM Fran\u00e7a de Almeida","year":"2026","unstructured":"Fran\u00e7a de Almeida CM, Alves AP, Ferreira MD, Moura de Carvalho Vicentini FT. Peptide-based vaccines: insights in a relationship between the explored administration routes and delivery systems. Int J Pharm. 2026. https:\/\/doi.org\/10.1016\/j.ijpharm.2026.126765.","journal-title":"Int J Pharm"},{"key":"848_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04241-9","author":"JB Haanen","year":"2026","unstructured":"Haanen JB, Schumacher TNM, Kagan JC, Fritsch EF, Wu CJ. Clinical development of cancer vaccines. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04241-9.","journal-title":"Nat Med"},{"key":"848_CR148","first-page":"498","volume":"61","author":"C Huang","year":"2026","unstructured":"Huang C, Wang H, Luo S, Yu C, Zhang L, Zhu D. Advances in delivery technologies-powered cancer vaccines. Bioact Mater. 2026;61:498\u2013533.","journal-title":"Bioact Mater"},{"key":"848_CR149","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0952-7915(00)00180-1","volume":"13","author":"C Th\u00e9ry","year":"2001","unstructured":"Th\u00e9ry C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol. 2001;13:45\u201351.","journal-title":"Curr Opin Immunol"},{"key":"848_CR150","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245\u201352.","journal-title":"Nature"},{"key":"848_CR151","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084190","author":"D Bencze","year":"2021","unstructured":"Bencze D, Fekete T, P\u00e1zm\u00e1ndi K. Type I interferon production of plasmacytoid dendritic cells under control. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22084190.","journal-title":"Int J Mol Sci"},{"key":"848_CR152","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/eji.201242796","volume":"43","author":"H el Bannoudi","year":"2013","unstructured":"el Bannoudi H, Han WG, Stoop JN, Louis-Plence P, Huizinga TW, Toes RE. DX5\u2009+\u2009CD4+ T cells modulate CD4\u2009+\u2009T-cell response via inhibition of IL-12 production by DCs. Eur J Immunol. 2013;43:439\u201346.","journal-title":"Eur J Immunol"},{"key":"848_CR153","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133\u201346.","journal-title":"Nat Rev Immunol"},{"key":"848_CR154","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/JLB.3MR0621-616RR","volume":"111","author":"YD Xu","year":"2022","unstructured":"Xu YD, Cheng M, Shang PP, Yang YQ. Role of IL-6 in dendritic cell functions. J Leukoc Biol. 2022;111:695\u2013709.","journal-title":"J Leukoc Biol"},{"key":"848_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02216","volume":"10","author":"Q Zeng","year":"2019","unstructured":"Zeng Q, Zhou Y, Schwarz H. CD137L-DCs, potent immune-stimulators-history, characteristics, and perspectives. Front Immunol. 2019;10:2216.","journal-title":"Front Immunol"},{"key":"848_CR156","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2741\/3279","volume":"14","author":"N Kadowaki","year":"2009","unstructured":"Kadowaki N. The divergence and interplay between pDC and mDC in humans. Front Biosci (Landmark Ed). 2009;14:808\u201317.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"848_CR157","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.trre.2019.05.001","volume":"33","author":"AW Thomson","year":"2019","unstructured":"Thomson AW, Metes DM, Ezzelarab MB, Ra\u00efch-Regu\u00e9 D. Regulatory dendritic cells for human organ transplantation. Transplant Rev (Orlando). 2019;33:130\u20136.","journal-title":"Transplant Rev (Orlando)"},{"key":"848_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101481","volume":"52","author":"AE Marciscano","year":"2021","unstructured":"Marciscano AE, Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol. 2021;52:101481.","journal-title":"Semin Immunol"},{"key":"848_CR159","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00257-2","volume":"11","author":"J Yu","year":"2022","unstructured":"Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol. 2022;11:3.","journal-title":"Exp Hematol Oncol"},{"key":"848_CR160","first-page":"209","volume":"26","author":"E Ovali","year":"2007","unstructured":"Ovali E, Dikmen T, Sonmez M, Yilmaz M, Unal A, Dalbasti T, Kuzeyli K, Erturk M, Omay SB. Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study. J Exp Clin Cancer Res. 2007;26:209\u201314.","journal-title":"J Exp Clin Cancer Res"},{"key":"848_CR161","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s00262-011-1192-2","volume":"61","author":"CJ Qi","year":"2012","unstructured":"Qi CJ, Ning YL, Han YS, Min HY, Ye H, Zhu YL, et al. Autologous dendritic cell vaccine for estrogen receptor (ER)\/progestin receptor (PR) double-negative breast cancer. Cancer Immunol Immunother. 2012;61:1415\u201324.","journal-title":"Cancer Immunol Immunother"},{"key":"848_CR162","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.intimp.2013.01.009","volume":"15","author":"LA Wolfraim","year":"2013","unstructured":"Wolfraim LA, Takahara M, Viley AM, Shivakumar R, Nieda M, Maekawa R, et al. Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL. Int Immunopharmacol. 2013;15:488\u201397.","journal-title":"Int Immunopharmacol"},{"key":"848_CR163","first-page":"2971","volume":"33","author":"T Kamigaki","year":"2013","unstructured":"Kamigaki T, Kaneko T, Naitoh K, Takahara M, Kondo T, Ibe H, Matsuda E, Maekawa R, Goto S. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors. Anticancer Res. 2013;33:2971\u20136.","journal-title":"Anticancer Res"},{"key":"848_CR164","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1016\/j.vaccine.2018.04.078","volume":"36","author":"GS Herbert","year":"2018","unstructured":"Herbert GS, Vreeland TJ, Clifton GT, Greene JM, Jackson DO, Hardin MO, Hale DF, Berry JS, Nichol P, Yin S, et al. Initial phase I\/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. Vaccine. 2018;36:3247\u201353.","journal-title":"Vaccine"},{"key":"848_CR165","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2217\/imt-2017-0114","volume":"10","author":"MO Hardin","year":"2018","unstructured":"Hardin MO, Vreeland TJ, Clifton GT, Hale DF, Herbert GS, Greene JM, et al. Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine. Immunotherapy. 2018;10:373\u201382.","journal-title":"Immunotherapy"},{"key":"848_CR166","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1245\/s10434-021-09709-1","volume":"28","author":"TJ Vreeland","year":"2021","unstructured":"Vreeland TJ, Clifton GT, Hale DF, Chick RC, Hickerson AT, Cindass JL, et al. A phase IIb randomized controlled trial of the TLPLDC vaccine as adjuvant therapy after surgical resection of stage III\/IV melanoma: a primary analysis. Ann Surg Oncol. 2021;28:6126\u201337.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"848_CR167","doi-asserted-by":"publisher","first-page":"e006665","DOI":"10.1136\/jitc-2023-006665","volume":"11","author":"EL Carpenter","year":"2023","unstructured":"Carpenter EL, Van Decar S, Adams AM, O\u2019Shea AE, McCarthy P, Chick RC, Clifton GT, Vreeland T, Valdera FA, Tiwari A, et al. Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III\/IV melanoma: a prespecified 36-month analysis. J Immunother Cancer. 2023;11(8):e006665.","journal-title":"J Immunother Cancer"},{"key":"848_CR168","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/cncr.20843","volume":"103","author":"GC Chang","year":"2005","unstructured":"Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM, et al. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer. 2005;103:763\u201371.","journal-title":"Cancer"},{"key":"848_CR169","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao5931","author":"JL Tanyi","year":"2018","unstructured":"Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018. https:\/\/doi.org\/10.1126\/scitranslmed.aao5931.","journal-title":"Sci Transl Med"},{"key":"848_CR170","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-13-1185","volume":"19","author":"CL Chiang","year":"2013","unstructured":"Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res. 2013;19:4801\u201315.","journal-title":"Clin Cancer Res"},{"key":"848_CR171","doi-asserted-by":"publisher","first-page":"e22664","DOI":"10.4161\/onci.22664","volume":"2","author":"LE Kandalaft","year":"2013","unstructured":"Kandalaft LE, Powell DJ Jr., Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology. 2013;2:e22664.","journal-title":"Oncoimmunology"},{"key":"848_CR172","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s00262-021-03075-3","volume":"71","author":"E Nickles","year":"2022","unstructured":"Nickles E, Dharmadhikari B, Yating L, Walsh RJ, Koh LP, Poon M, et al. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit. Cancer Immunol Immunother. 2022;71:1531\u201343.","journal-title":"Cancer Immunol Immunother"},{"key":"848_CR173","doi-asserted-by":"publisher","first-page":"126765","DOI":"10.1016\/j.ijpharm.2026.126765","volume":"694","author":"CMF de Almeida","year":"2026","unstructured":"de Almeida CMF, Alves AP, Ferreira MD, Vicentini F. Peptide-based vaccines: insights in a relationship between the explored administration routes and delivery systems. Int J Pharm. 2026;694:126765.","journal-title":"Int J Pharm"},{"key":"848_CR174","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"848_CR175","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2165\/00126839-200607030-00006","volume":"7","author":"-T Sipuleucel","year":"2006","unstructured":"Sipuleucel -T. APC 8015, APC-8015, prostate cancer vaccine\u2013Dendreon. Drugs R D. 2006;7:197\u2013201.","journal-title":"Drugs R D"},{"key":"848_CR176","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/CJI.0000000000000063","volume":"38","author":"RL Prue","year":"2015","unstructured":"Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D\u2019Rozario R, Waterhouse NJ, Rossetti T, Coleman R, Tracey C, et al. A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer. J Immunother. 2015;38:71\u20136.","journal-title":"J Immunother"},{"key":"848_CR177","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/ijc.34382","volume":"152","author":"C Sun","year":"2023","unstructured":"Sun C, Nagaoka K, Kobayashi Y, Maejima K, Nakagawa H, Nakajima J, et al. Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumors. Int J Cancer. 2023;152:1463\u201375.","journal-title":"Int J Cancer"},{"key":"848_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101516","volume":"5","author":"J Ingels","year":"2024","unstructured":"Ingels J, De Cock L, Stevens D, Mayer RL, Th\u00e9ry F, Sanchez GS, et al. Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. Cell Rep Med. 2024;5:101516.","journal-title":"Cell Rep Med"},{"key":"848_CR179","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00448-5","volume":"6","author":"Z Ding","year":"2021","unstructured":"Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther. 2021;6:26.","journal-title":"Signal Transduct Target Ther"},{"key":"848_CR180","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1007\/s12032-012-0312-y","volume":"29","author":"Z Yu","year":"2012","unstructured":"Yu Z, Qian J, Wu J, Gao J, Zhang M. Allogeneic mRNA-based electrotransfection of autologous dendritic cells and specific antitumor effects against osteosarcoma in rats. Med Oncol. 2012;29:3440\u20138.","journal-title":"Med Oncol"},{"key":"848_CR181","doi-asserted-by":"publisher","first-page":"973","DOI":"10.4161\/cbt.8.10.8281","volume":"8","author":"Z Yu","year":"2009","unstructured":"Yu Z, Sun H, Zhang T, Yang T, Long H, Ma B. Specific antitumor effects of tumor vaccine produced by autologous dendritic cells transfected with allogeneic osteosarcoma total RNA through electroporation in rats. Cancer Biol Ther. 2009;8:973\u201380.","journal-title":"Cancer Biol Ther"},{"key":"848_CR182","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","volume":"24","author":"S Wilgenhof","year":"2013","unstructured":"Wilgenhof S, Van Nuffel AMT, Benteyn D, Corthals J, Aerts C, Heirman C, et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol. 2013;24:2686\u201393.","journal-title":"Ann Oncol"},{"key":"848_CR183","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s00262-020-02618-4","volume":"69","author":"Y Jansen","year":"2020","unstructured":"Jansen Y, Kruse V, Corthals J, Schats K, van Dam PJ, Seremet T, Heirman C, Brochez L, Kockx M, Thielemans K, Neyns B. A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III\/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunol Immunother. 2020;69:2589\u201398.","journal-title":"Cancer Immunol Immunother"},{"key":"848_CR184","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/jjco\/hyp194","volume":"40","author":"H Sugiyama","year":"2010","unstructured":"Sugiyama H. WT1 (Wilms\u2019 tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010;40:377\u201387.","journal-title":"Jpn J Clin Oncol"},{"key":"848_CR185","first-page":"5495","volume":"33","author":"A Coosemans","year":"2013","unstructured":"Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, Vergote I, Amant F, SW VANG. Wilms\u2019 Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I\/II clinical trial. Anticancer Res. 2013;33:5495\u2013500.","journal-title":"Anticancer Res"},{"key":"848_CR186","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13045-025-01661-x","volume":"18","author":"ZN Berneman","year":"2025","unstructured":"Berneman ZN, De Laere M, Germonpr\u00e9 P, Huizing MT, Willemen Y, Lion E, De Reu H, Van den Bossche J, Van den Brande J, Specenier P, et al. WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome. J Hematol Oncol. 2025;18:9.","journal-title":"J Hematol Oncol"},{"key":"848_CR187","unstructured":"Phase A. I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemoradiation for the Adjuvant Treatment of Adult Glioblastoma. (Baylor College of M, Philadelphia College of Osteopathic M eds.). 2020."},{"key":"848_CR188","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1200\/JCO.23.02585","volume":"42","author":"FR van \u2019t Land","year":"2024","unstructured":"van \u2018t Land FR, Willemsen M, Bezemer K, van der Burg SH, van den Bosch TPP, Doukas M, Fellah A, Kolijn PM, Langerak AW, Moskie M, et al. Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer. J Clin Oncol. 2024;42:3083\u201393.","journal-title":"J Clin Oncol"},{"key":"848_CR189","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1212\/WNL.0000000000211043","volume":"104","author":"JJ Zhu","year":"2025","unstructured":"Zhu JJ, Esquenazi Y, Hsu S, Zvavanjanja R, Vu M, Schumann E, Trivedi A, Liu W, Namekar MS, Hofferek CJ, Ernste KJ. Phase I Analysis of DOC1021, A Cell-based Vaccination Platform for Adjuvant Therapy of Glioblastoma\u00a0(S29.004). Neurology. 2025;104:3493.","journal-title":"Neurology"},{"key":"848_CR190","unstructured":"Randomized Study of DOC1021 Dendritic Cell Immunotherapy in. Combination With Standard of Care for Newly Diagnosed Adult Glioblastoma. 2025."},{"key":"848_CR191","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"848_CR192","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/vaccines10060879","volume":"10","author":"SL Gupta","year":"2022","unstructured":"Gupta SL, Khan N, Basu S, Soni V. B-cell-based immunotherapy: a promising new alternative. Vaccines. 2022;10(6):879.","journal-title":"Vaccines."},{"key":"848_CR193","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2018.12.001","volume":"73","author":"R Tokunaga","year":"2019","unstructured":"Tokunaga R, Naseem M, Lo JH, Battaglin F, Soni S, Puccini A, et al. B cell and B cell-related pathways for novel cancer treatments. Cancer Treat Rev. 2019;73:10\u20139.","journal-title":"Cancer Treat Rev"},{"key":"848_CR194","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","volume":"23","author":"G Oliveira","year":"2023","unstructured":"Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023;23:295\u2013316.","journal-title":"Nat Rev Cancer"},{"key":"848_CR195","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1158\/1078-0432.CCR-21-0697","volume":"27","author":"SS Kim","year":"2021","unstructured":"Kim SS, Sumner WA, Miyauchi S, Cohen EEW, Califano JA, Sharabi AB. Role of B cells in responses to checkpoint blockade immunotherapy and overall survival of cancer patients. Clin Cancer Res. 2021;27:6075\u201382.","journal-title":"Clin Cancer Res"},{"key":"848_CR196","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1023\/B:JOCI.0000040928.67495.52","volume":"24","author":"ML Disis","year":"2004","unstructured":"Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2\/neu peptide based vaccine in cancer patients. J Clin Immunol. 2004;24:571\u20138.","journal-title":"J Clin Immunol"},{"key":"848_CR197","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1200\/JCO.2009.22.3883","volume":"27","author":"PT Kaumaya","year":"2009","unstructured":"Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and\/or recurrent solid tumors. J Clin Oncol. 2009;27:5270\u20137.","journal-title":"J Clin Oncol"},{"key":"848_CR198","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.molmed.2025.03.010","volume":"31","author":"P Verdys","year":"2025","unstructured":"Verdys P, Johansen AZ, Gupta A, Presti M, Dionisio E, Madsen DH, et al. Acquired resistance to immunotherapy in solid tumors. Trends Mol Med. 2025;31:1008\u201320.","journal-title":"Trends Mol Med"},{"issue":"9","key":"848_CR199","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/j.jtho.2022.07.204","volume":"17","author":"GE Richardson","year":"2022","unstructured":"Richardson GE, Park JJ, Boyer MJ, Gutierrez M, Carbone DP, Savvides P, et al. P1.15-08 Phase 1: IMU-201 (PD1-Vaxx), a B-cell immunotherapy as monotherapy or in combination with atezolizumab, in adults with non-small cell lung cancer. J Thorac Oncol. 2022;17:S123.","journal-title":"J Thorac Oncol"},{"key":"848_CR200","unstructured":"Phase A. II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer. (Australasian Gastro-Intestinal Trials G ed. 2024."},{"key":"848_CR201","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352805","volume":"15","author":"V Albarr\u00e1n","year":"2024","unstructured":"Albarr\u00e1n V, San Rom\u00e1n M, Pozas J, Chamorro J, Rosero DI, Guerrero P, et al. Adoptive T cell therapy for solid tumors: current landscape and future challenges. Front Immunol. 2024;15:1352805.","journal-title":"Front Immunol"},{"key":"848_CR202","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"Yang X, Yang C, Zhang S, Geng H, Zhu AX, Bernards R, et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024;42:180\u201397.","journal-title":"Cancer Cell"},{"key":"848_CR203","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"848_CR204","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add0887","volume":"14","author":"AC Obenauf","year":"2022","unstructured":"Obenauf AC. Mechanism-based combination therapies for metastatic cancer. Sci Transl Med. 2022;14:eadd0887.","journal-title":"Sci Transl Med"},{"key":"848_CR205","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-03020-3","volume":"22","author":"N Sun","year":"2024","unstructured":"Sun N, Wang T, Zhang S. Radionuclide-labelled nanoparticles for cancer combination therapy: a review. J Nanobiotechnol. 2024;22:728.","journal-title":"J Nanobiotechnol"},{"key":"848_CR206","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23:445\u201360.","journal-title":"Nat Rev Drug Discov"},{"key":"848_CR207","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201734","volume":"9","author":"Z Li","year":"2022","unstructured":"Li Z, Lai X, Fu S, Ren L, Cai H, Zhang H, et al. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv Sci. 2022;9:e2201734.","journal-title":"Adv Sci"},{"key":"848_CR208","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1074477","volume":"13","author":"S Zhu","year":"2022","unstructured":"Zhu S, Wang Y, Tang J, Cao M. Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment. Front Immunol. 2022;13:1074477.","journal-title":"Front Immunol"},{"key":"848_CR209","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2026.2679142","author":"AJ Leber","year":"2026","unstructured":"Leber AJ, Hontecillas R, Tubau-Juni N, Bassaganya-Riera J. Immunometabolic mechanisms of ionizing radiation in a mouse model of gastrointestinal acute radiation syndrome. Int J Radiat Biol. 2026. https:\/\/doi.org\/10.1080\/09553002.2026.2679142.","journal-title":"Int J Radiat Biol"},{"key":"848_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7:258.","journal-title":"Signal Transduct Target Ther"},{"key":"848_CR211","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40364-024-00628-3","volume":"12","author":"X Wang","year":"2024","unstructured":"Wang X, Zhang H, XinZhang, Liu Y. Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy. Biomark Res. 2024;12:98.","journal-title":"Biomark Res"},{"key":"848_CR212","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2017.05.005","volume":"187","author":"L Urbanova","year":"2017","unstructured":"Urbanova L, Hradilova N, Moserova I, Vosahlikova S, Sadilkova L, Hensler M, et al. High hydrostatic pressure affects antigenic pool in tumor cells: implication for dendritic cell-based cancer immunotherapy. Immunol Lett. 2017;187:27\u201334.","journal-title":"Immunol Lett"},{"key":"848_CR213","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100334","volume":"7","author":"R Zhong","year":"2022","unstructured":"Zhong R, Ling X, Cao S, Xu J, Zhang B, Zhang X, et al. Safety and efficacy of dendritic cell-based immunotherapy (DCVAC\/LuCa) combined with carboplatin\/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. ESMO Open. 2022;7:100334.","journal-title":"ESMO Open"},{"key":"848_CR214","first-page":"100427","volume":"28","author":"M Zemanova","year":"2021","unstructured":"Zemanova M, Cernovska M, Havel L, Bartek T, Lukesova S, Jakesova J, Vanasek J, Reiterer P, Kultan J, Andrasina I, et al. Autologous dendritic cell-based immunotherapy (DCVAC\/LuCa) and carboplatin\/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I\/II trial. Cancer Treat Res Commun. 2021;28:100427.","journal-title":"Cancer Treat Res Commun"},{"key":"848_CR215","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ygyno.2021.07.003","volume":"162","author":"D Cibula","year":"2021","unstructured":"Cibula D, Rob L, Mallmann P, Knapp P, Klat J, Chovanec J, et al. Dendritic cell-based immunotherapy (DCVAC\/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): a randomized, open-label, phase 2 trial. Gynecol Oncol. 2021;162:652\u201360.","journal-title":"Gynecol Oncol"},{"key":"848_CR216","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003190","author":"L Rob","year":"2022","unstructured":"Rob L, Cibula D, Knapp P, Mallmann P, Klat J, Minar L, et al. Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003190.","journal-title":"J Immunother Cancer"},{"key":"848_CR217","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, et al. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. 2023;9:112\u201321.","journal-title":"JAMA Oncol"},{"key":"848_CR218","first-page":"2217","volume":"38","author":"R Yanagisawa","year":"2018","unstructured":"Yanagisawa R, Koizumi T, Koya T, Sano K, Koido S, Nagai K, Kobayashi M, Okamoto M, Sugiyama H, Shimodaira S. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. Anticancer Res. 2018;38:2217\u201325.","journal-title":"Anticancer Res"},{"key":"848_CR219","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009765","author":"S Koido","year":"2024","unstructured":"Koido S, Taguchi J, Shimabuku M, Kan S, Bito T, Misawa T, et al. Dendritic cells pulsed with multifunctional Wilms\u2019 tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-009765.","journal-title":"J Immunother Cancer"},{"key":"848_CR220","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.trecan.2024.06.003","volume":"10","author":"A Brandenburg","year":"2024","unstructured":"Brandenburg A, Heine A, Brossart P. Next-generation cancer vaccines and emerging immunotherapy combinations. Trends Cancer. 2024;10:749\u201369.","journal-title":"Trends Cancer"},{"key":"848_CR221","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov. 2021;11:1368\u201397.","journal-title":"Cancer Discov"},{"key":"848_CR222","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","volume":"8","author":"NJ Vogelzang","year":"2022","unstructured":"Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, et al. Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022;8:546\u201352.","journal-title":"JAMA Oncol"},{"key":"848_CR223","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/annonc\/mdy089","volume":"29","author":"ME Rodr\u00edguez-Ruiz","year":"2018","unstructured":"Rodr\u00edguez-Ruiz ME, Perez-Gracia JL, Rodr\u00edguez I, Alfaro C, O\u00f1ate C, P\u00e9rez G, Gil-Bazo I, Benito A, Inog\u00e9s S, L\u00f3pez-Diaz de Cerio A, et al. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Ann Oncol. 2018;29:1312\u20139.","journal-title":"Ann Oncol"},{"key":"848_CR224","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","volume":"24","author":"SGC Kroeze","year":"2023","unstructured":"Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, Alongi F, Ricardi U, Jereczek-Fossa BA, Westhoff P, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023;24:e121\u201332.","journal-title":"Lancet Oncol"},{"key":"848_CR225","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213222","volume":"14","author":"Y Shi","year":"2023","unstructured":"Shi Y, Ma X, He D, Dong B, Qiao T. Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy. Front Immunol. 2023;14:1213222.","journal-title":"Front Immunol"},{"key":"848_CR226","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03751-0","volume":"73","author":"M Vounckx","year":"2024","unstructured":"Vounckx M, Tijtgat J, Stevens L, Dirven I, Ilsen B, Vandenbroucke F, et al. A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab\/ipilimumab plus CD1c (BDCA-1)(+)\/CD141 (BDCA-3)(+) myeloid dendritic cells in solid tumors. Cancer Immunol Immunother. 2024;73:167.","journal-title":"Cancer Immunol Immunother"},{"key":"848_CR227","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1016\/j.ymthe.2024.12.057","volume":"33","author":"H Hosseinalizadeh","year":"2025","unstructured":"Hosseinalizadeh H, Wang LS, Mirzaei H, Amoozgar Z, Tian L, Yu J. Emerging combined CAR-NK cell therapies in cancer treatment: Finding a dancing partner. Mol Ther. 2025;33:2406\u201325.","journal-title":"Mol Ther"},{"key":"848_CR228","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116532","volume":"174","author":"W Szlasa","year":"2024","unstructured":"Szlasa W, Sztuder A, Kaczmar-Dybko A, Maciejczyk A, Dybko J. Efficient combination of radiotherapy and CAR-T - a systematic review. Biomed Pharmacother. 2024;174:116532.","journal-title":"Biomed Pharmacother"},{"key":"848_CR229","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41420-024-02245-3","volume":"10","author":"X Ma","year":"2024","unstructured":"Ma X, Zhang W, Zeng M, Asavasupreechar T, Kang S, Li Y, Yu L. Systemic tumor regression with synergy therapy: radiotherapy and CAR-T. Cell Death Discov. 2024;10:479.","journal-title":"Cell Death Discov"},{"key":"848_CR230","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.21037\/jgo-2025-564","volume":"16","author":"X Zhang","year":"2025","unstructured":"Zhang X, Shi H, Qiu L, Gao Z, Xu J, Zhou X, Xia Z, Radhakrishna G, Xue J, Qin S. Local radiotherapy polarized tumor-associated macrophages enhance the efficacy of Claudin18.2-targeted CAR-T therapy in pancreatic cancer. J Gastrointest Oncol. 2025;16:1682\u201398.","journal-title":"J Gastrointest Oncol"},{"key":"848_CR231","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01995-y","volume":"22","author":"NMF Abdalsalam","year":"2024","unstructured":"Abdalsalam NMF, Ibrahim A, Saliu MA, Liu TM, Wan X, Yan D. MDSC: a new potential breakthrough in CAR-T therapy for solid tumors. Cell Commun Signal. 2024;22:612.","journal-title":"Cell Commun Signal"},{"key":"848_CR232","doi-asserted-by":"publisher","first-page":"1140541","DOI":"10.3389\/fimmu.2023.1140541","volume":"14","author":"AX Wang","year":"2023","unstructured":"Wang AX, Ong XJ, D\u2019Souza C, Neeson PJ, Zhu JJ. Combining chemotherapy with CAR-T cell therapy in treating solid tumors. Front Immunol. 2023;14:1140541.","journal-title":"Front Immunol"},{"key":"848_CR233","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03817-z","volume":"74","author":"M Khaliulin","year":"2024","unstructured":"Khaliulin M, Valiullina A, Petukhov A, Yuan Y, Spada S, Bulatov E. Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells. Cancer Immunol Immunother. 2024;74:3.","journal-title":"Cancer Immunol Immunother"},{"key":"848_CR234","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ac4c2f","author":"CMC Ma","year":"2022","unstructured":"Ma CMC. Pulsed low dose-rate radiotherapy: radiobiology and dosimetry. Phys Med Biol. 2022. https:\/\/doi.org\/10.1088\/1361-6560\/ac4c2f.","journal-title":"Phys Med Biol"},{"key":"848_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110213","volume":"194","author":"S Zhou","year":"2024","unstructured":"Zhou S, Zhu M, Wei X, Mu P, Shen L, Wang Y, et al. Low-dose radiotherapy synergizes with iRGD-antiCD3-modified T cells by facilitating T cell infiltration. Radiother Oncol. 2024;194:110213.","journal-title":"Radiother Oncol"},{"key":"848_CR236","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105181","volume":"220","author":"P Loap","year":"2026","unstructured":"Loap P, Sarkozy C, Dendale R, Kirova Y. Optimizing bridging radiotherapy prior to CAR-T cell therapy: an evidence-based approach. Crit Rev Oncol Hematol. 2026;220:105181.","journal-title":"Crit Rev Oncol Hematol"},{"key":"848_CR237","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","volume":"105","author":"AJ Sim","year":"2019","unstructured":"Sim AJ, Jain MD, Figura NB, Chavez JC, Shah BD, Khimani F, Lazaryan A, Krivenko G, Davila ML, Liu HD, et al. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2019;105:1012\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"848_CR238","unstructured":"Hypofractionated radiation in combination With B7-H3-CAR T cells for pediatric patients with relapsed\/refractory sarcomas. 2025."},{"key":"848_CR239","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009636","author":"J Yan","year":"2024","unstructured":"Yan J, Xie Y, Liu Z, Yang Y, Zhou T. DLL4-targeted CAR-T therapy sensitizes neoadjuvant chemotherapy via eliminating cancer stem cells and reshaping immune microenvironment in HER2(+) breast cancer. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-009636.","journal-title":"J Immunother Cancer"},{"key":"848_CR240","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Rivi\u00e8re I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817\u201328.","journal-title":"Blood"},{"key":"848_CR241","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007162","author":"S Papa","year":"2023","unstructured":"Papa S, Adami A, Metoudi M, Beatson R, George MS, Achkova D, et al. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007162.","journal-title":"J Immunother Cancer"},{"key":"848_CR242","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2217\/imt.14.120","volume":"7","author":"LM Whilding","year":"2015","unstructured":"Whilding LM, Maher J. ErbB-targeted CAR T-cell immunotherapy of cancer. Immunotherapy. 2015;7:229\u201341.","journal-title":"Immunotherapy"},{"key":"848_CR243","doi-asserted-by":"publisher","first-page":"e1434464","DOI":"10.1080\/2162402X.2018.1434464","volume":"7","author":"CM Suryadevara","year":"2018","unstructured":"Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, et al. Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. Oncoimmunology. 2018;7:e1434464.","journal-title":"Oncoimmunology"},{"key":"848_CR244","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41571-023-00794-7","volume":"20","author":"G Mountzios","year":"2023","unstructured":"Mountzios G, Remon J, Hendriks LEL, Garc\u00eda-Campelo R, Rolfo C, Van Schil P, et al. Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Nat Rev Clin Oncol. 2023;20:664\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"848_CR245","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ymthe.2025.01.047","volume":"33","author":"J Shi","year":"2025","unstructured":"Shi J, Zhang Z, Chen HY, Yao Y, Ke S, Yu K, Shi J, Xiao X, He C, Xiang B, et al. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy. Mol Ther. 2025;33:1073\u201390.","journal-title":"Mol Ther"},{"key":"848_CR246","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130\u201344.","journal-title":"J Clin Invest"},{"key":"848_CR247","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"GR Khosravi","year":"2024","unstructured":"Khosravi GR, Mostafavi S, Bastan S, Ebrahimi N, Gharibvand RS, Eskandari N. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. 2024;44:521\u201353.","journal-title":"Cancer Commun"},{"key":"848_CR248","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12935-021-02407-8","volume":"22","author":"S Vafaei","year":"2022","unstructured":"Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H, Zamani M. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int. 2022;22:2.","journal-title":"Cancer Cell Int"},{"key":"848_CR249","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4049\/jimmunol.2300077","volume":"211","author":"BG Vincent","year":"2023","unstructured":"Vincent BG, File DM, McKinnon KP, Moore DT, Frelinger JA, Collins EJ, et al. Efficacy of a dual-epitope dendritic cell vaccine as part of combined immunotherapy for HER2-expressing breast tumors. J Immunol. 2023;211:219\u201328.","journal-title":"J Immunol"},{"key":"848_CR250","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00262-014-1558-3","volume":"63","author":"S Van Lint","year":"2014","unstructured":"Van Lint S, Wilgenhof S, Heirman C, Corthals J, Breckpot K, Bonehill A, et al. Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. Cancer Immunol Immunother. 2014;63:959\u201367.","journal-title":"Cancer Immunol Immunother"},{"key":"848_CR251","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","volume":"5","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, Nasrallah MP, et al. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat Rev Cancer. 2024;5:517\u201331.","journal-title":"Nat Rev Cancer"},{"key":"848_CR252","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00504-8","volume":"13","author":"W Shao","year":"2024","unstructured":"Shao W, Yao Y, Yang L, Li X, Ge T, Zheng Y, et al. Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy. Exp Hematol Oncol. 2024;13:37.","journal-title":"Exp Hematol Oncol"},{"key":"848_CR253","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","volume":"11","author":"M Aldea","year":"2021","unstructured":"Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria JC. Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. Cancer Discov. 2021;11:874\u201399.","journal-title":"Cancer Discov"},{"key":"848_CR254","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.euros.2022.03.012","volume":"40","author":"M Lindskog","year":"2022","unstructured":"Lindskog M, Laurell A, Kjellman A, Melichar B, Rey PM, Zieli\u0144ski H, Villacampa F, Bigot P, Zoltan B, Parikh O, et al. Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. Eur Urol Open Sci. 2022;40:38\u201345.","journal-title":"Eur Urol Open Sci"},{"key":"848_CR255","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-19-2427","volume":"26","author":"RA Figlin","year":"2020","unstructured":"Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DYT, Master V, Kapoor A, Vaena D, Lowrance W, Bratslavsky G, et al. Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020;26:2327\u201336.","journal-title":"Clin Cancer Res"},{"key":"848_CR256","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0255-0","volume":"5","author":"A Laurell","year":"2017","unstructured":"Laurell A, L\u00f6nnemark M, Brekkan E, Magnusson A, Tolf A, Wallgren AC, et al. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. J Immunother Cancer. 2017;5:52.","journal-title":"J Immunother Cancer"},{"key":"848_CR257","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41551-024-01216-4","volume":"9","author":"DKY Zhang","year":"2025","unstructured":"Zhang DKY, Brockman JM, Adu-Berchie K, Liu Y, Binenbaum Y, de L\u00e1zaro I, et al. Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells. Nat Biomed Eng. 2025;9:268\u201378.","journal-title":"Nat Biomed Eng"},{"key":"848_CR258","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jconrel.2024.04.040","volume":"370","author":"VV Inamdar","year":"2024","unstructured":"Inamdar VV, Hao S, Stephan SB, Stephan MT. Biomaterial-based scaffolds for direct in situ programming of tumor-infiltrating T lymphocytes. J Control Release. 2024;370:310\u20137.","journal-title":"J Control Release"},{"key":"848_CR259","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122580","volume":"308","author":"S Pandit","year":"2024","unstructured":"Pandit S, Agarwalla P, Song F, Jansson A, Dotti G, Brudno Y. Implantable CAR T cell factories enhance solid tumor treatment. Biomaterials. 2024;308:122580.","journal-title":"Biomaterials"},{"key":"848_CR260","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2023.103020","volume":"84","author":"M Hong","year":"2023","unstructured":"Hong M, Talluri S, Chen YY. Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors. Curr Opin Biotechnol. 2023;84:103020.","journal-title":"Curr Opin Biotechnol"},{"key":"848_CR261","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583116","volume":"16","author":"LY Cao","year":"2025","unstructured":"Cao LY, Zhao Y, Chen Y, Ma P, Xie JC, Pan XM, et al. CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights. Front Immunol. 2025;16:1583116.","journal-title":"Front Immunol"},{"key":"848_CR262","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-025-00931-7","author":"Z Tu","year":"2025","unstructured":"Tu Z, Chen Y, Zhang Z, Meng W, Li L. Barriers and solutions for CAR-T therapy in solid tumors. Cancer Gene Ther. 2025. https:\/\/doi.org\/10.1038\/s41417-025-00931-7.","journal-title":"Cancer Gene Ther"},{"key":"848_CR263","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01211-z","author":"AU Kabir","year":"2025","unstructured":"Kabir AU, Subramanian M, Kwon Y, Choi K. Linking tumour angiogenesis and tumour immunity. Nat Rev Immunol. 2025. https:\/\/doi.org\/10.1038\/s41577-025-01211-z.","journal-title":"Nat Rev Immunol"},{"key":"848_CR264","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2025106","author":"M Xu","year":"2025","unstructured":"Xu M, Fei J, Xiao ZX, Yi Y. Energy stress and adaptation strategy of tumor cells in different microenvironments: from primary tumors to distant metastases. Acta Biochim Biophys Sin (Shanghai). 2025. https:\/\/doi.org\/10.3724\/abbs.2025106.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"848_CR265","doi-asserted-by":"publisher","DOI":"10.3389\/or.2025.1617487","volume":"19","author":"HH Lee","year":"2025","unstructured":"Lee HH, Al-Ogaili Z. Fibroblast activation protein and the tumour microenvironment: challenges and therapeutic opportunities. Oncol Rev. 2025;19:1617487.","journal-title":"Oncol Rev"},{"key":"848_CR266","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70292","volume":"6","author":"Y Li","year":"2020","unstructured":"Li Y, Liu Q, Jing X, Wang Y, Jia X, Yang X, et al. Cancer-associated fibroblasts: heterogeneity, cancer pathogenesis, and therapeutic targets. MedComm. 2020;6:e70292.","journal-title":"MedComm"},{"key":"848_CR267","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12916-025-03926-1","volume":"23","author":"S Lin","year":"2025","unstructured":"Lin S, Liu D, Liang T, Zhuang Y, Wang X, Ma S, Li Q, Hu K. Cryoablation-induced modulation of Treg cells and the TGF-\u03b2 pathway in lung adenocarcinoma: implications for increased antitumor immunity. BMC Med. 2025;23:89.","journal-title":"BMC Med"},{"key":"848_CR268","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231417","author":"M M\u00e9nard","year":"2025","unstructured":"M\u00e9nard M, Yoda H, Nasholm N, Barata MJ, Wang L, Simonds EF, et al. Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma. J Exp Med. 2025. https:\/\/doi.org\/10.1084\/jem.20231417.","journal-title":"J Exp Med"},{"key":"848_CR269","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011310","author":"H Peng","year":"2025","unstructured":"Peng H, Pan Y, Sun Y, Wang X, Fan X, Wang Y, et al. Hyperglycemia induces an immunosuppressive microenvironment in colorectal cancer liver metastases by recruiting peripheral blood monocytes through the CCL3-CCR1 axis. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-011310.","journal-title":"J Immunother Cancer"},{"key":"848_CR270","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02354-2","volume":"24","author":"J Yang","year":"2025","unstructured":"Yang J, Lu X, Cai Q, Liu M, Xia T, Hong D, et al. Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma. Mol Cancer. 2025;24:158.","journal-title":"Mol Cancer"},{"key":"848_CR271","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.120389","volume":"353","author":"H Shen","year":"2025","unstructured":"Shen H, Jiang Y, Wang L, Hu Z, Zhang S, Cui J, et al. Jiawei Yanghe decoction augments intratumoral CD8(+) TIL infiltration and enhances radiotherapy efficacy in non-small cell lung cancer through CXCR3 ligand-mediated chemotaxis. J Ethnopharmacol. 2025;353:120389.","journal-title":"J Ethnopharmacol"},{"key":"848_CR272","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102116","volume":"50","author":"M Mannewitz","year":"2024","unstructured":"Mannewitz M, Kolben T, Perleberg C, Meister S, Hahn L, Mitter S, et al. CCL22 as an independent prognostic factor in endometrial cancer patients. Transl Oncol. 2024;50:102116.","journal-title":"Transl Oncol"},{"key":"848_CR273","doi-asserted-by":"publisher","first-page":"89","DOI":"10.47162\/RJME.66.1.08","volume":"66","author":"L Rusu","year":"2025","unstructured":"Rusu L, Mihai TA, Schenker RA, Marin MI, Schenker M, Streba CT, et al. The effect of physical exercises on TNF-\u03b1, IL-6, and IL-8 cytokines expression and NK cells in cancer. Rom J Morphol Embryol. 2025;66:89\u201398.","journal-title":"Rom J Morphol Embryol"},{"key":"848_CR274","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06866-9","volume":"23","author":"X Hu","year":"2025","unstructured":"Hu X, Ge C, Huang C, He D, Yao X, Cheng J, et al. Enhanced homing and efficacy of HER2-CAR T cells via CXCR5\/CCR6 co-expression for HER2-positive NSCLC. J Transl Med. 2025;23:863.","journal-title":"J Transl Med"},{"key":"848_CR275","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005433","author":"A Li","year":"2022","unstructured":"Li A, Chang Y, Song NJ, Wu X, Chung D, Riesenberg BP, et al. Selective targeting of GARP-LTGF\u03b2 axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8(+) T cell antitumor immunity. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005433.","journal-title":"J Immunother Cancer"},{"key":"848_CR276","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100804","author":"YR Li","year":"2025","unstructured":"Li YR, Li Z, Zhu Y, Li M, Chen Y, Lee D, et al. Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med (Baltimore). 2025. https:\/\/doi.org\/10.1016\/j.medj.2025.100804.","journal-title":"Med (Baltimore)"},{"key":"848_CR277","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012288","author":"R Paredes","year":"2025","unstructured":"Paredes R, Borea R, Drago F, Russo A, Nigita G, Rolfo C. Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1, SMARCA4, and PTEN mutations. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-012288.","journal-title":"J Immunother Cancer"},{"key":"848_CR278","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00262-024-03909-w","volume":"74","author":"Y Tian","year":"2025","unstructured":"Tian Y, Zhang L, Ping Y, Zhang Z, Yao C, Shen C, Li F, Wen C, Zhang Y. CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors. Cancer Immunol Immunother. 2025;74:55.","journal-title":"Cancer Immunol Immunother"},{"key":"848_CR279","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/cac2.12010","volume":"40","author":"W Zhang","year":"2020","unstructured":"Zhang W, Wang H, Sun M, Deng X, Wu X, Ma Y, Li M, Shuoa SM, You Q, Miao L. CXCL5\/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun (Lond). 2020;40:69\u201380.","journal-title":"Cancer Commun (Lond)"},{"key":"848_CR280","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1158\/1078-0432.CCR-23-3298","volume":"30","author":"LJ Talbot","year":"2024","unstructured":"Talbot LJ, Chabot A, Ross AB, Beckett A, Nguyen P, Fleming A, Chockley PJ, Shepphard H, Wang J, Gottschalk S, DeRenzo C. Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models. Clin Cancer Res. 2024;30:4434\u201349.","journal-title":"Clin Cancer Res"},{"key":"848_CR281","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell. 2019;35:489-503.e488.","journal-title":"Cancer Cell"},{"key":"848_CR282","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","author":"JH Choe","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021. https:\/\/doi.org\/10.1126\/scitranslmed.abe7378.","journal-title":"Sci Transl Med"},{"key":"848_CR283","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100227","volume":"2","author":"P Kosti","year":"2021","unstructured":"Kosti P, Opzoomer JW, Larios-Martinez KI, Henley-Smith R, Scudamore CL, Okesola M, et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med. 2021;2:100227.","journal-title":"Cell Rep Med"},{"key":"848_CR284","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s43018-026-01124-3","volume":"7","author":"Y Gao","year":"2026","unstructured":"Gao Y, Li J, Zhang H, Zhang Y, Qian S, Zhu X, et al. Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial. Nat Cancer. 2026;7:608\u201321.","journal-title":"Nat Cancer"},{"key":"848_CR285","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.semcancer.2025.07.004","volume":"114","author":"Y Lu","year":"2025","unstructured":"Lu Y, Stoof J, Tano\u00e9 YR, Walsh N, Bijlsma MF, Lei H, et al. CRISPR\/Cas9 genome engineering in PDAC: from preclinical studies to translation and clinical research. Semin Cancer Biol. 2025;114:242\u201355.","journal-title":"Semin Cancer Biol"},{"key":"848_CR286","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.123079","volume":"317","author":"ARK Kumar","year":"2025","unstructured":"Kumar ARK, Low J, Lim J, Myint B, Sun X, Wu L, et al. Non-viral, high throughput genetic engineering of primary immune cells using nanostraw-mediated transfection. Biomaterials. 2025;317:123079.","journal-title":"Biomaterials"},{"key":"848_CR287","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","volume":"609","author":"J Carnevale","year":"2022","unstructured":"Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O\u2019Leary P, et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022;609:174\u201382.","journal-title":"Nature"},{"key":"848_CR288","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18:2188\u201398.","journal-title":"Cell Mol Immunol"},{"key":"848_CR289","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(25)00083-X","volume":"26","author":"E Lou","year":"2025","unstructured":"Lou E, Choudhry MS, Starr TK, Folsom TD, Bell J, Rathmann B, et al. Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. Lancet Oncol. 2025;26:559\u201370.","journal-title":"Lancet Oncol"},{"key":"848_CR290","doi-asserted-by":"publisher","first-page":"e006522","DOI":"10.1136\/jitc-2022-006522","volume":"11","author":"K Lontos","year":"2023","unstructured":"Lontos K, Wang Y, Joshi SK, Frisch AT, Watson MJ, Kumar A, Menk AV, Wang Y, Cumberland R, Lohmueller J, et al. Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor T-cell therapy against solid tumors. J Immunother Cancer. 2023;11:e006522.","journal-title":"J Immunother Cancer"},{"key":"848_CR291","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cmet.2022.02.009","volume":"34","author":"L Ye","year":"2022","unstructured":"Ye L, Park JJ, Peng L, Yang Q, Chow RD, Dong MB, Lam SZ, Guo J, Tang E, Zhang Y, et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metabol. 2022;34:595\u2013e614514.","journal-title":"Cell Metabol"},{"key":"848_CR292","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101250","volume":"32","author":"J Dias","year":"2024","unstructured":"Dias J, Garcia J, Agliardi G, Roddie C. CAR-T cell manufacturing landscape-lessons from the past decade and considerations for early clinical development. Mol Ther Methods Clin Dev. 2024;32:101250.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"848_CR293","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","volume":"22","author":"C Diorio","year":"2025","unstructured":"Diorio C, Teachey DT, Grupp SA. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks. Nat Rev Clin Oncol. 2025;22:10\u201327.","journal-title":"Nat Rev Clin Oncol"},{"key":"848_CR294","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-026-09850-7","author":"MA Waqar","year":"2026","unstructured":"Waqar MA, Malik A, Mubarak N. Recent advancements and persisting challenges in the evolution of next generation car t cell therapy for solid malignancies: a comprehensive review. Immunol Res. 2026. https:\/\/doi.org\/10.1007\/s12026-026-09850-7.","journal-title":"Immunol Res"},{"key":"848_CR295","doi-asserted-by":"publisher","first-page":"e70612","DOI":"10.1002\/cncr.70612","volume":"132","author":"K Loo","year":"2026","unstructured":"Loo K, Betof AS. Top advances of the year in autologous cellular therapy in melanoma and solid tumors. Cancer. 2026;132:e70612.","journal-title":"Cancer"},{"key":"848_CR296","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1846926","volume":"9","author":"H Dai","year":"2020","unstructured":"Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020;9:1846926.","journal-title":"Oncoimmunology"},{"key":"848_CR297","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157726","author":"H Huang","year":"2022","unstructured":"Huang H, Nie CP, Liu XF, Song B, Yue JH, Xu JX, et al. Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI157726.","journal-title":"J Clin Invest"},{"key":"848_CR298","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","volume":"31","author":"FJ Lowery","year":"2025","unstructured":"Lowery FJ, Goff SL, Gasmi B, Parkhurst MR, Ratnam NM, Halas HK, Shelton TE, Langhan MM, Bhasin A, Dinerman AJ, et al. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. Nat Med. 2025;31:1994\u20132003.","journal-title":"Nat Med"},{"key":"848_CR299","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s00262-020-02572-1","volume":"69","author":"A Khammari","year":"2020","unstructured":"Khammari A, Nguyen JM, Leccia MT, Guillot B, Saiagh S, Pandolfino MC, et al. Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial. Cancer Immunol Immunother. 2020;69:1663\u201372.","journal-title":"Cancer Immunol Immunother"},{"key":"848_CR300","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112965","volume":"191","author":"YJ Liang","year":"2023","unstructured":"Liang YJ, Chen QY, Xu JX, Liu XF, Xia JC, Liu LT, et al. A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients. Eur J Cancer. 2023;191:112965.","journal-title":"Eur J Cancer"},{"key":"848_CR301","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101133","volume":"4","author":"Q Pan","year":"2023","unstructured":"Pan Q, Weng D, Liu J, Han Z, Ou Y, Xu B, et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma. Cell Rep Med. 2023;4:101133.","journal-title":"Cell Rep Med"},{"key":"848_CR302","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","volume":"31","author":"M Wermke","year":"2025","unstructured":"Wermke M, Araujo DM, Chatterjee M, Tsimberidou AM, Holderried TAW, Jazaeri AA, et al. Autologous T cell therapy for PRAME(+) advanced solid tumors in HLA-A*02(+) patients: a phase 1 trial. Nat Med. 2025;31:2365\u201374.","journal-title":"Nat Med"},{"key":"848_CR303","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1158\/1078-0432.CCR-24-0742","volume":"30","author":"J Tobias","year":"2024","unstructured":"Tobias J, Maglakelidze M, Andri\u0107 Z, Ryspayeva D, Bulat I, Nikoli\u0107 I, Petrovi\u0107 Z, Chawla T, Nagarkar R, Garner-Spitzer E, et al. Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON). Clin Cancer Res. 2024;30:4044\u201354.","journal-title":"Clin Cancer Res"},{"key":"848_CR304","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12967-017-1202-z","volume":"15","author":"S Inog\u00e9s","year":"2017","unstructured":"Inog\u00e9s S, Tejada S, de Cerio AL, G\u00e1llego P\u00e9rez-Larraya J, Espin\u00f3s J, Idoate MA, Dom\u00ednguez PD, de Eulate RG, Aristu J, Bendandi M, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med. 2017;15:104.","journal-title":"J Transl Med"},{"key":"848_CR305","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, Ferstl B, Klobuch S, Bokemeyer C, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29:2844\u201353.","journal-title":"Nat Med"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00848-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00848-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00848-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:02:16Z","timestamp":1792674136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00848-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":305,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00848-3","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"12 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have given consent for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"109"}}